FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
Crossref DOI link: https://doi.org/10.1038/s41392-021-00590-8
Published Online: 2021-04-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
He, Xuemei
Wang, Manni
Wu, Min http://orcid.org/0000-0003-1205-982X
Text and Data Mining valid from 2021-04-09
Version of Record valid from 2021-04-09
Article History
Received: 21 February 2021
Revised: 22 March 2021
Accepted: 23 March 2021
First Online: 9 April 2021
Competing interests
: The authors declare no competing interests.